Entity guide
Who makes retatrutide?
Retatrutide is an investigational molecule from Eli Lilly. Public pages using names such as Synedica retatrutide, Veltrane Gold retatrutide, or other supplier-style labels should not be treated as Lilly products or approved medicines unless an official source says so.
Key takeaways
- Lilly is the company publicly associated with retatrutide clinical development.
- Lilly says retatrutide is investigational and not yet available for public use.
- Supplier names in search results are source-page claims, not approval signals.
- This site tracks listings for verification, not endorsement.
Lilly and retatrutide
Lilly's retatrutide FAQ describes the molecule, its investigational status, and the Phase 3 clinical-trial program. ClinicalTrials.gov records for retatrutide also list Eli Lilly and Company as sponsor or responsible party for multiple studies.
Why other names appear in search
Search results can include marketplaces, peptide suppliers, reseller pages, forum posts, and brand-like labels. Queries such as retatrutide synedica, synedica retatrutide, or Veltrane Gold retatrutide are best handled as source-verification tasks. The presence of a brand-like name does not answer whether the product is approved, lawful, or appropriate for personal use.
How to verify an entity claim
- Check whether the page is from Lilly, FDA, ClinicalTrials.gov, or another official source.
- Look for clear manufacturer, sponsor, or responsible-party language.
- Separate catalog labels from official approval or availability statements.
- Use this site's methodology page to understand how listing claims are captured.
Sources
Public record review
Have a public record we should add?
Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.